[go: up one dir, main page]

BR0316126A - Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica - Google Patents

Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica

Info

Publication number
BR0316126A
BR0316126A BR0316126-9A BR0316126A BR0316126A BR 0316126 A BR0316126 A BR 0316126A BR 0316126 A BR0316126 A BR 0316126A BR 0316126 A BR0316126 A BR 0316126A
Authority
BR
Brazil
Prior art keywords
combination
lymphocytic leukemia
chronic lymphocytic
treatment
compounds
Prior art date
Application number
BR0316126-9A
Other languages
English (en)
Inventor
Lawrence Carl Panasci
Raquel Silvia Aloyz
Original Assignee
Jewish General Hospital
Lawrence Carl Panasci
Raquel Silvia Aloyz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jewish General Hospital, Lawrence Carl Panasci, Raquel Silvia Aloyz filed Critical Jewish General Hospital
Publication of BR0316126A publication Critical patent/BR0316126A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"COMBINAçãO DE COMPOSTOS PARA O TRATAMENTO DE LEUCEMIA LINFOCìTICA CRÈNICA". A presente invenção refere-se a uma combinação que compreende (a) um análogo de mostarda nitrogenada selecionado de clorambucil, clornafazina, estramustina, mecloretamina, cloridrato de óxido de mecloretamina, navembiquina, fenestrina, prednimustina, trofosfamida ou uracil mostrada e (b) 4-(4-metilpiperazin-1-ilmetil)-N-¢4-metil-3-(4-piridin-3-il)pirimidin-2-ilamin o)fenil!-benzamida de fórmula ou um sal farmaceuticamente aceitável deste, a invenção refere-se ao uso da referida combinação para o tratamento de leucemia linfocítica crónica.
BR0316126-9A 2002-11-12 2003-11-10 Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica BR0316126A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42548102P 2002-11-12 2002-11-12
PCT/IB2003/005454 WO2004043466A1 (en) 2002-11-12 2003-11-10 Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia

Publications (1)

Publication Number Publication Date
BR0316126A true BR0316126A (pt) 2005-09-27

Family

ID=32312996

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316126-9A BR0316126A (pt) 2002-11-12 2003-11-10 Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica

Country Status (11)

Country Link
US (2) US20060122186A1 (pt)
EP (1) EP1578426B1 (pt)
JP (1) JP4854198B2 (pt)
CN (1) CN100475212C (pt)
AT (1) ATE468855T1 (pt)
AU (1) AU2003280191A1 (pt)
BR (1) BR0316126A (pt)
CA (1) CA2504665C (pt)
DE (1) DE60332762D1 (pt)
ES (1) ES2348140T3 (pt)
WO (1) WO2004043466A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100386115C (zh) * 2004-10-14 2008-05-07 孔庆忠 一种抗癌药物组合物
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
PL2240172T3 (pl) * 2007-12-21 2014-08-29 Novartis Ag Kombinacja nilotynibu i chlorambucylu do leczenia przewlekłej białaczki limfocytowej
EP2273876B1 (en) * 2008-03-27 2019-03-06 Helsinn Healthcare SA Stabilized compositions of alkylating agents and methods of using same
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
JP2016519684A (ja) * 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
CN105997981A (zh) * 2016-06-13 2016-10-12 崔坤峰 苯丁酸氮芥的药物组合物及其抗抑郁的医药用途
JP7001529B2 (ja) 2018-04-13 2022-01-19 デンカ株式会社 治具及び製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506257A (en) * 1992-03-26 1996-04-09 University Of British Columbia Aminocyclohexylamides for antiarrhythmic and anaesthetic uses
CN1088777A (zh) * 1992-12-18 1994-07-06 丛繁滋 用于癌病灶直接给药的化疗药物制剂的制备方法
US20050261283A1 (en) * 2002-05-13 2005-11-24 Vikas Sukhatme Methods and compositions for the treatment of graft failure

Also Published As

Publication number Publication date
CN100475212C (zh) 2009-04-08
JP4854198B2 (ja) 2012-01-18
DE60332762D1 (de) 2010-07-08
US20060122186A1 (en) 2006-06-08
US8492383B2 (en) 2013-07-23
CN1711090A (zh) 2005-12-21
WO2004043466A1 (en) 2004-05-27
JP2006508118A (ja) 2006-03-09
ES2348140T3 (es) 2010-11-30
CA2504665C (en) 2012-12-18
US20090312290A1 (en) 2009-12-17
CA2504665A1 (en) 2004-05-27
ATE468855T1 (de) 2010-06-15
AU2003280191A1 (en) 2004-06-03
EP1578426A1 (en) 2005-09-28
EP1578426B1 (en) 2010-05-26

Similar Documents

Publication Publication Date Title
DK1332137T3 (da) Behandling af gastrointestinale stromale tumorer
MY128664A (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
IL177005A0 (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
BR0314112A (pt) Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia
BR0316126A (pt) Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica
DK1471916T3 (da) Behandling af rheumatoid arthritis under anvendelse af imatinib
HK1087638A1 (en) Use of tyrosine kinase inhibitors to treat diabetes
ATE386528T1 (de) Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs
AU2003244922A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis
RS52014B (sr) Nova so benzoilgvanidina
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
WO2004103374A3 (en) Imatinib combinations for head and neck cancers

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2281 DE 23/09/2014.